NCT04937166View on ClinicalTrials.gov

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Interventions
BIOLOGICAL

DSP107

DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

DRUG

Azacitidine

Azacitidine is an analog of the pyrimidine nucleoside cytidine.

DRUG

Venetoclax

Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor

Trial Locations (2)

77030

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

Kahr Medical
All Listed Sponsors
lead

Kahr Medical

INDUSTRY